Letter to Congress June 17, 2020 re: CBD

CSPI Urges FDA to Take Steps to Reduce Risks of Cannabis Use

From CSPI, CFA, Consumer Reports, Public Health Institute

CSPI, the Consumer Federation of America, Consumer Reports, and the Public Health Institute sent this letter to again urge Congress to reject any attempts to force federal regulators to immediately legalize cannabidiol (CBD) use in dietary supplements and food products.

It is clear that Congress is not the right evaluator of the safety of consumer products, and a political decision to legislatively override a careful and scientific evaluation of CBD safety would create terrible precedent. More well-funded profiteers would inevitably barrage Congress with requests for their chosen products to be given carte blanche, bypassing oversight that assures safety and quality. For their part, consumers would wrongly believe that products have been evaluated while potentially being put at risk.

View resource